Active Biotech AB (publ) (ACTI.ST)
- Previous Close
0.4965 - Open
0.4870 - Bid 0.4525 x --
- Ask 0.4530 x --
- Day's Range
0.4505 - 0.4870 - 52 Week Range
0.4005 - 1.4780 - Volume
376,898 - Avg. Volume
259,962 - Market Cap (intraday)
163.901M - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1600 - Earnings Date Aug 22, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.50
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
www.activebiotech.comRecent News: ACTI.ST
View MorePerformance Overview: ACTI.ST
Trailing total returns as of 8/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACTI.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACTI.ST
View MoreValuation Measures
Market Cap
179.64M
Enterprise Value
147.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.94
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-77.43%
Return on Equity (ttm)
-207.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-44.8M
Diluted EPS (ttm)
-0.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
25.4M
Total Debt/Equity (mrq)
12.94%
Levered Free Cash Flow (ttm)
-28.6M